NightHawk Biosciences Inc (NHWK)

[dia76ca]

The final slide in the Austria presentation is interesting.
*********************

Conclusions and Future Directions
Presentation Number: 4650, Viagenpumatucel-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary
Data From The DURGA Trial – Daniel Morgensztern, MD

• There have been no additional toxicities for combination of Viagenpumatucel-L plus nivolumab compared to
existing data on single agent immune checkpoint inhibitors alone.
• Immune responses may correlate with clinical efficacy
• The phase 1b part of the study is still ongoing and the expansion phase will be determined based on the
preliminary ORR
• Additional combinations with chemotherapy, anti-CTLA-4 and other T-cell co-stimulators being considered
• Manufacturing started for the second generation vaccine ComPACT, which incorporates OX40-L costimulatory molecule
********************

It is the "additional combinations" which most interests me. It could mean many new arms to the DURGA trial. I would expect a Opdivo/Yervoy + HS-110 and/or HS-120 arm. As for chemotherapy combinations....might they add low-dose cyclophosphamide to some of these combinations? They have some experience with it!